Charles A. Nicolette
Vorstandsvorsitzender bei CoImmune, Inc.
Profil
Charles A.
Nicolette is currently the Chief Executive Officer & Director at CoImmune, Inc. Previously, he held the position of Director-Antigen Discovery at Genzyme Molecular Oncology and Director at Antigen Discovery.
From 2007 to 2018, he served as the Chief Scientific Officer at Argos Therapeutics, Inc. Dr. Nicolette obtained his undergraduate and doctorate degrees from The State University of New York.
Aktive Positionen von Charles A. Nicolette
| Unternehmen | Position | Beginn |
|---|---|---|
CoImmune, Inc.
 CoImmune, Inc. Pharmaceuticals: MajorHealth Technology CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Charles A. Nicolette
| Unternehmen | Position | Ende |
|---|---|---|
| ARGOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 30.11.2018 |
Genzyme Molecular Oncology
 Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Molecular Oncology is a company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis. | Corporate Officer/Principal | 01.01.2003 |
| Antigen Discovery | Direktor/Vorstandsmitglied | 01.01.2003 |
Ausbildung von Charles A. Nicolette
| The State University of New York | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Molecular Oncology is a company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis. | Health Technology |
| Antigen Discovery | |
CoImmune, Inc.
CoImmune, Inc. Pharmaceuticals: MajorHealth Technology CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC. | Health Technology |
